KRAS and non-small cell lung carcinoma: Survival analysis demonstrated that 19 patients with metastatic KRAS+/TP53+ NSCLC had a median OS of 19.5 months (95% CI, 15.7-23.4 months) from initial metastasis diagnosis and 7 months (95% CI, 2.1-12 months) from initial phase I clinic visit.